How to Know if Your Fibroids Are Shrinking?

Lighter periods, less pelvic pressure, and a flatter-feeling abdomen are the everyday clues that fibroids may be getting smaller, but the only way to confirm shrinkage is with imaging, usually ultrasound or MRI. The tricky part is that symptom relief and actual volume reduction do not always move in lockstep, and even imaging has its quirks when it comes to measuring change over time.

Symptom Changes That Suggest Shrinkage

Fibroids cause trouble mainly through bulk and blood flow. A large fibroid pressing on the bladder makes you urinate constantly; one distorting the uterine lining can cause heavy, prolonged periods; several packed together can make your lower abdomen visibly protrude. When fibroids shrink, those mechanical pressures ease, and the symptoms they drove tend to improve in a recognizable pattern.

The changes most women notice first are menstrual. Periods that were lasting eight or nine days may drop back to five or six. The volume of bleeding decreases, and the passage of large clots becomes less frequent. If you were soaking through a pad or tampon every hour during your heaviest days, you may find you can go two or three hours. For many women, the bleeding improvement is the single most meaningful sign, because it is the symptom that disrupts daily life most.

Pelvic pressure and urinary frequency tend to improve more gradually, because they depend on overall fibroid bulk rather than surface-level changes to the uterine lining. You may realize you are sleeping through the night without a bathroom trip, or that the sensation of fullness in your lower belly has faded. Constipation or difficulty emptying the bladder, if those were fibroid-related, also eases as tumors lose volume. Pain during sex, particularly deep-thrust pain, can diminish as well.

The Uterine Fibroid Symptom and Quality of Life questionnaire, known as the UFS-QOL, is a standardized tool clinicians use to track exactly these kinds of changes over time.¹ It covers symptom severity and quality-of-life subscales like energy, self-consciousness, and sexual function. Studies have shown it is highly responsive to treatment-related changes, with large improvements visible within six months of effective therapy.² If your doctor has not mentioned it, you can ask about using the UFS-QOL as a before-and-after benchmark, especially if you are starting medication or preparing for a procedure.

Why Symptoms Alone Are Not Enough

Here is the frustrating reality: you can feel dramatically better while your fibroids have barely budged, or you can have measurable shrinkage on a scan without much symptom relief. The disconnect happens because symptoms depend on where the fibroid sits and what it pushes against, not just how big it is. A fibroid that shrinks from six centimeters to four centimeters but still sits right on top of the bladder may continue to cause urinary frequency. Conversely, a submucosal fibroid (one that bulges into the uterine cavity) might shrink only modestly but produce a huge reduction in bleeding because even a small decrease in its footprint on the lining makes a difference.

Symptom improvement is a useful signal, but confirming actual shrinkage requires imaging.

Ultrasound and Its Measurement Limits

Transvaginal ultrasound is the standard first-line tool for checking fibroid size. It is affordable, widely available, and does not involve radiation. Your doctor measures the fibroid in two or three dimensions, and those numbers go into your chart as a baseline for future comparison. The catch is that ultrasound measurements are less precise than many patients assume.

A study specifically designed to measure intra-observer variation found that as much as a 20 percent increase in fibroid diameter from one scan to the next could be due to measurement error rather than true growth.³ The same logic applies in reverse: a small decrease might not represent real shrinkage. Factors like how full your bladder is, the angle of the probe, bowel gas, and body habitus all introduce variability. This does not mean ultrasound is useless for tracking change. It means that a single follow-up scan showing a modest size difference should be interpreted cautiously. When your doctor says “let’s recheck in three to six months,” part of the reason is to see a consistent trend rather than relying on one measurement.

For women with many fibroids, a very large uterus, or fibroids in hard-to-reach locations, ultrasound becomes less reliable. In those situations, MRI is the more accurate option.

MRI for More Precise Tracking

MRI gives a three-dimensional, high-contrast picture of the uterus that is far less operator-dependent than ultrasound. Reader-to-reader agreement on MRI-based fibroid measurements is very high.⁴ That consistency makes MRI particularly valuable when you need to know whether a treatment is working or a fibroid is truly shrinking versus staying stable.

In clinical trials, MRI can detect volumetric changes relatively early. One study using serial MRI found a measurable treatment effect by day 14 of medication, with treated fibroids showing a roughly 9 percent median volume reduction while untreated fibroids grew by the same amount.⁵ Changes in blood flow within the fibroid, assessed using contrast-enhanced MRI, became visible around two to three months. In routine clinical care, you will not typically get an MRI two weeks into treatment, but the research shows that real structural changes begin early even when they are not yet large enough to feel.

MRI is also better at distinguishing between different types of tissue change inside a fibroid. A shrinking fibroid often undergoes degeneration, and MRI can tell whether that degeneration is hyaline (the most common type, accounting for about 60 percent of cases), cystic, or hemorrhagic.⁶ Degeneration is generally a sign that the fibroid is losing its blood supply and involuting, which is exactly what you want to see. Calcification is another marker of involution and is sometimes picked up incidentally on other imaging.

How Different Treatments Produce Shrinkage

If you are actively treating fibroids, the timeline and magnitude of shrinkage depend heavily on the approach. Knowing what to expect helps you set realistic benchmarks for your follow-up scans.

Uterine Artery Embolization

Uterine artery embolization (UAE) works by cutting off blood supply to the fibroids. A large cohort study found that the biggest drop in uterine volume happened in the first three months after the procedure, while fibroid-specific volume continued falling most steeply between three and six months. By 12 months, about two-thirds of patients had achieved greater than 50 percent fibroid volume reduction.⁷ If your post-UAE ultrasound at three months shows only modest change, that does not necessarily mean the procedure failed. The fibroid may still be in the process of losing perfusion and shrinking.

Focused Ultrasound (HIFU)

High-intensity focused ultrasound destroys fibroid tissue with targeted heat. Size reduction typically begins about one month after treatment and becomes clearly visible by three months.⁸ Reported volume reductions in studies have ranged widely, from around 9 percent at 12 months in one study to over 30 percent at three to six months in others. The amount of tissue successfully destroyed during the procedure, measured as the non-perfused volume immediately afterward, is a strong predictor of how much the fibroid will eventually shrink. HIFU tends to work best on smaller, less vascular fibroids.⁹

Radiofrequency Ablation

Radiofrequency ablation (RFA) uses heat delivered through a needle or probe inserted into the fibroid. A case series found that average fibroid volume dropped by about 54 percent, with blood flow scores falling by roughly 60 percent.¹⁰ Like HIFU, the amount of shrinkage depends on how completely the fibroid tissue was ablated during the procedure.

Medications

GnRH agonists and newer oral GnRH antagonists are commonly prescribed to shrink fibroids before surgery or to manage symptoms. One comparison found that the oral antagonist relugolix produced a measurable decrease in fibroid diameter by eight weeks, while the injectable agonist leuprorelin did not show a statistically significant diameter change at any single time point during the study period, though it did reduce blood flow.¹¹ A major limitation of GnRH-based therapies is that fibroids tend to regrow after treatment stops, and the medications carry side effects related to low estrogen.¹²

Selective progesterone receptor modulators like ulipristal acetate (UPA) have been studied for their ability to shrink fibroids through a different mechanism. UPA appears to slow fibroid cell proliferation and remodel the dense connective tissue matrix that gives fibroids their bulk.¹³ In clinical trials, the percentage of women achieving at least a 25 percent volume reduction increased with repeated treatment courses, climbing from about 62 percent after the first course to 78 percent after four courses.¹⁴ Availability of UPA varies by country due to safety concerns about rare but serious liver injury, so check with your doctor about whether it is an option where you live.

When Menopause Does the Work

Fibroids are fueled by estrogen and progesterone, so when hormone levels drop after menopause, fibroids typically shrink on their own. A 10-year retrospective study tracking 97 postmenopausal women found that shrinkage was fastest in the first two years after menopause, with the rate of volume change nearly four points per year faster during that early window compared to years three through ten.¹⁵ Two factors predicted greater shrinkage: having a normal body weight (BMI under 25) and having fewer fibroids. Women with a BMI under 25 had a 10-year shrinkage rate of about 25 percent, compared to roughly 16 percent for women with a higher BMI. Women with a single fibroid shrank more than those with four or more.

The body-weight connection makes biological sense. Fat tissue produces estrogen even after the ovaries slow down, so carrying extra weight partially offsets the hormonal drop that drives postmenopausal fibroid involution. If you are approaching menopause and hoping your fibroids will handle themselves, maintaining a healthy weight may help that process along, though no trial has tested weight loss as a direct intervention for fibroid shrinkage.

Postpartum Regression

Fibroids sometimes grow during pregnancy because of surging hormones, but a substantial number shrink dramatically afterward. One study following women in the postpartum period found that 72 percent experienced fibroid regression of more than 50 percent.¹⁶ In rare cases, fibroids can even disappear entirely. A case report documented a large fibroid that shrank steadily after a second vaginal delivery and was completely gone four years later.¹⁷

If you had fibroids during pregnancy and your postpartum symptoms seem milder than before, it is worth getting a follow-up ultrasound to see where things stand rather than assuming the fibroids are unchanged. The postpartum hormone shift can produce real, lasting regression.

Green Tea Extract and Vitamin D

Among supplements, green tea extract (specifically the compound EGCG) has the most direct clinical evidence for fibroid shrinkage. In a small pilot trial, women taking 800 mg per day of green tea extract saw their total fibroid volume drop by about a third over the study period, while the placebo group’s fibroids actually grew by about a quarter.¹⁸ Symptom severity scores improved by a similar magnitude. A separate pilot study combining vitamin D and green tea extract reported a roughly 18 percent reduction in mean fibroid size at the patient level and about 37 percent at the individual fibroid level, with intramural fibroids responding better than subserosal ones.¹⁹

A recent review summarizing the evidence from laboratory, animal, and human studies concluded that both vitamin D and EGCG show promise for fibroid treatment, with complementary mechanisms: vitamin D appears to inhibit fibroid cell growth and reduce fibrosis, while EGCG promotes programmed cell death and blocks proliferation pathways.²⁰ The results are encouraging, but the clinical trials so far have been small. No large randomized trial has confirmed these findings, so it would be premature to rely on supplements as a primary treatment for significant fibroids. They may be a reasonable add-on, especially for women who want to try a low-risk approach alongside watchful waiting.

How to Talk to Your Doctor About Tracking

If you are actively monitoring fibroids, whether on medication, post-procedure, or just watching and waiting, a few practical steps make tracking more reliable.

First, try to get your follow-up scans at the same facility, ideally with the same sonographer. Measurement variability is lower when the same person uses the same equipment and the same technique each time. If you switch providers, bring the prior imaging or have it sent so the new team can compare directly.

Second, ask your doctor to track volume rather than just diameter. A fibroid that goes from 5 cm to 4 cm in its widest dimension has not shrunk by 20 percent in volume; because volume scales with the cube of the radius, that one-centimeter drop can represent a roughly 50 percent volume reduction depending on shape. Volume gives you a much more accurate picture of change than any single linear measurement.

Third, keep a symptom diary. Note the number of days of your period, how many pads or tampons you use on your heaviest day, whether you are passing clots, how often you get up at night to urinate, and any pelvic pain. When you combine that diary with imaging, you and your doctor can see whether symptom relief matches the structural changes or whether something else might be going on.

When a Fibroid Shrinks but Feels Worse

Occasionally, a fibroid in the process of shrinking causes new or different symptoms rather than relief. This typically happens during degeneration. Red degeneration, for example, involves hemorrhagic infarction of the fibroid tissue and can cause acute pain, tenderness, and sometimes low-grade fever. It is most commonly seen during pregnancy but can occur at other times, including after UAE or as a fibroid outgrows its blood supply on its own. Hyaline degeneration is usually painless, but cystic degeneration can occasionally cause discomfort as fluid accumulates inside the fibroid.

After uterine artery embolization, a phenomenon called post-embolization syndrome, involving cramping, nausea, fatigue, and sometimes mild fever, is common in the first week and is essentially the body responding to fibroid tissue dying. It is uncomfortable but usually self-limiting, and its presence actually suggests the procedure worked. If you experience severe or worsening pain after any fibroid treatment, contact your doctor to rule out infection or other complications, but know that some discomfort during the shrinkage process can be normal.

Fibroids That Will Not Shrink

Not every fibroid responds to treatment, and some characteristics make shrinkage less likely. Very large fibroids with well-established blood supplies can be resistant to embolization or ablation. Calcified fibroids, which have already undergone a kind of natural hardening, do not respond well to hormonal therapies because the living tissue that would be affected by hormones has already been replaced by calcium deposits. Pedunculated fibroids, which dangle from the uterus on a stalk, are generally not good candidates for embolization due to a risk of the stalk detaching.

If your imaging shows no shrinkage after a reasonable treatment course, your doctor may revisit the treatment plan. Sometimes a fibroid that does not respond to one approach will respond to another, or surgical removal may become the better option. The absence of shrinkage is not a failure on your part; it is information that points toward a different strategy.